Published:
AMDL Subsidiary Donates Pharmaceuticals in China Earthquake Relief Effort
AMDL Subsidiary Donates Pharmaceuticals in China Earthquake Relief Effort
TUSTIN, Calif., May 14 /PRNewswire-FirstCall/ -- AMDL, Inc.
(Amex: ADL), headquartered inTustin, California, with operations inShenzhen,
Jiangxi, andJilin, China, is a vertically integrated specialty pharmaceutical
company. Along with its subsidiary Jade Pharmaceutical Inc. (JPI), AMDL
engages in the research, development, manufacture, and marketing of
diagnostic, pharmaceutical, nutritional supplement, and cosmetic products
currently inChina. The Company today announced that JPI has donated various
pharmaceutical products valued at more than $70,000, to the China Red Cross
(Chengdu Branch) to provide medical support to the victims of the recent
earthquake located in Shichuan Province, which devastated portions ofChina.
"Not only did our JPI management make this significant donation valued at
more than $70,000, it initiated a special trip toSichuan to ensure that the
drugs reached the proper destinations," said Gary Dreher, CEO of AMDL. "The
initiative taken by JPI signals its awareness and enthusiasm for its social
responsibility. We do not expect that this earthquake will have any negative
impact on sales of JJB and or YYB products, in fact, certain products may
experience a higher than normal sales growth rate due to the disaster."
About Jade Pharmaceutical: JPI has access to the fastest growing
pharmaceutical and consumer market in the world:China. AMDL, through its
subsidiaries, Jade currently manufactures large volume injection fluids,
tablets and other related products, holding licenses for 133 products. It also
manufactures 107 generic, over the counter and supplemental pharmaceutical
products under certified Chinese Good Manufacturing Practice (CGMP) standards.
About AMDL: More information about AMDL and its products can be obtained
at http://www.amdl.com.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. Such statements are
subject to certain risks and uncertainties, and actual circumstances, events
or results may differ materially from those projected in such forward-looking
statements. The Company cautions readers not to place undue reliance on any
forward-looking statements. The Company does not undertake, and specifically
disclaims any obligation, to update or revise such statements to reflect new
circumstances or unanticipated events as they occur.
Contact: AMDL, Inc.
Mr. Paul Knopick
AMDL Investor Relations
Direct Line: 949.707.5365
VoiceMail: 714.505.4460
SOURCE AMDL, Inc.
Copyright © 2008, PRNewswire
Copyright © 2008, NewsBlaze,
Daily NewsTags: Healthcare, Pharmaceuticals, Health, california
_ _Is your favorite bookmark site missing?
Ask for it.
Search News
Daily News
